GLP1R and Stroke: GLP-1 receptor agonists significantly reduced major adverse cardiovascular events, cardiovascular and all-cause mortality, stroke, coronary revascularization, and kidney outcomes, with consistent benefits across sex, CVD history, BMI, and kidney function